Status: Recruiting
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Participants needed: 18
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Brown UniversityUpdated: Aug 20, 2026Locations: 1
Eligibility criteria
Histologically confirmed diagnosis of colorectal adenocarcinoma [+9]
Prior yttrium-90 therapy [+34]